Aug 2026
Integrated network pharmacology, molecular docking, and experimental validation reveal synergistic inhibition of EGFR and PI3K-Akt/JAK2-STAT3 pathways by Esculin and Esculetin to exert anti-colorectal cancer effects.
It is demonstrated that esculin and esculetin co-target EGFR and simultaneously block downstream PI3K-Akt and JAK2-STAT3 dual pathways, providing a multi-component, multi-target, multi-pathway synergistic model for C. fraxini-based combination therapy against CRC.
Lin Liao, Zhao-Hui Tang, P. Luo et al.
· Toxicology and Applied Pharm... · 0 citations